• Skip to primary navigation
  • Skip to main content
SRI logo
  • About
    • Press room
    • Our history
  • Expertise
    • Advanced imaging systems
    • Artificial intelligence
    • Biomedical R&D services
    • Biomedical sciences
    • Computer vision
    • Cyber & formal methods
    • Education and learning
    • Innovation strategy and policy
    • National security
    • Ocean & space
    • Quantum
    • QED-C
    • Robotics, sensors & devices
    • Speech & natural language
    • Video test & measurement
  • Ventures
  • NSIC
  • Careers
  • Contact
  • 日本支社
Search
Close
Bios September 8, 2021

Carol Green

Senior Director, Preclinical Development

Carol Green, Ph.D., DABT, is an accomplished scientist with expertise in toxicology, absorption, distribution, metabolism, and excretion studies. In her current role, she is the principal investigator for four National Institutes of Health contracts and one research grant.

Her research includes developing new in vitro human tissue models to predict toxicity of pharmaceuticals and environmental chemicals, and advancing the preclinical development of promising pharmaceutical candidates against chemical threat agents. She also provides preclinical pharmacology and toxicology data on anti-infective agents, cancer chemopreventive and therapeutic agents, and other pharmaceuticals. Green oversees the development of data included in Investigational New Drug applications and has served on project teams for more than 10 drugs that have moved into Phase I trials.

Green has authored or co-authored 57 published papers and 98 abstracts. She is a diplomate for the American Board of Toxicology, and past president of the Genetic and Environmental Toxicology Association of Northern California. She received a Ph.D. in pharmacology and toxicology from the University of California, Davis, and conducted postdoctoral work in biochemical toxicology at SRI.

Recent publications

more +
A tandem liquid chromatography and tandem mass spectrometry (LC/LC–MS/MS) technique to separate and quantify steroid isomers 11β-methyl-19-nortestosterone and testosterone  (3/21/2022) - Here we describe a high-sensitivity LC/LC-MS/MS method that combines chiral chromatography and reverse-phase chromatography.
Pharmacokinetics and Safety Studies in Rodent Models Support Development of EPICERTIN as a Novel Topical Wound-Healing Biologic for Ulcerative Colitis  (3/1/2022) - This study established for the first time the pharmacokinetics, bioavailability, and acute safety of EPICERTIN in healthy and dextran sodium…
Enhancement of sensitivity and quantification quality in the LC-MS/MS measurement of large biomolecules with sum of MRM (SMRM) (2/8/2022) - We describe here an approach to boost detection sensitivity and expand dynamic range in the quantitation of large molecules while…

How can we help?

Once you hit send…

We’ll match your inquiry to the person who can best help you.

Expect a response within 48 hours.

Career call to action image

Make your own mark.

Search jobs

Our work

Case studies

Publications

Timeline of innovation

Areas of expertise

Institute

Leadership

Press room

Media inquiries

Compliance

Careers

Job listings

Contact

SRI Ventures

Our locations

Headquarters

333 Ravenswood Ave
Menlo Park, CA 94025 USA

+1 (650) 859-2000

Subscribe to our newsletter


日本支社
SRI International
  • Contact us
  • Privacy Policy
  • Cookies
  • DMCA
  • Copyright © 2022 SRI International